by Jim Lane (Biofuels Digest) For many people, a key question in the advanced bioeconomy continues to be: “what is Amyris becoming, and when, and where and how?”
Becoming a global leader in the health and beauty market, and self-funding operations in 2018 with at least $10 million in EBITDA this year — those are the targets appearing out of Emeryville now.
Amyris’ President of R&D, Joel Cherry, gave this presentations on Amyris technology and the outlook from 2018 and beyond in recent weeks — an illuminating overview of Amyris’ promise and progress on multiple fronts. READ MORE